Immunotherapeutic effects of dendritic cells pulsed with a coden-optimized HPV 16 E6 and E7 fusion gene in vivo and in vitro

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 9, 2015, Pages 3843-3847

  Zhou, Zhi Xiang ^a   Li, Dan ^a   Guan, Shan Shan ^a   Zhao, Chen ^a   Li, Ze Lin ^a   Zeng, Yi ^a,b  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cervical cancer; Dendritic cells; E6; E7; Human papillomavirus 16; Vaccine

Indexed keywords

CANCER VACCINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN;

ADENOVIRIDAE; ANIMAL; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MOUSE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CANCER VACCINES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 84930168059     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.9.3843     Document Type: Article

References (21)

1. Aggarwal P (2014). Cervical cancer: can it be prevented? World J Clin Oncol, 5, 775-80.
2. Bellone S, Pecorelli S, Cannon MJ, et al (2007). Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther, 7, 1473-86.
3. Chansaenroj J, Theamboonlers A, et al (2012). Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev, 13, 599-606.
4. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
5. Jiang P, Yue Y (2014). Human papillomavirus oncoproteins and apoptosis (Review). Exp Ther Med, 7, 3-7.
6. Kozlowska A, Mackiewicz J, Mackiewicz A (2013). Therapeutic gene modified cell based cancer vaccines. Gene, 525, 200-7.
7. Lutz MB, Kukutsch N, Ogilvie ALJ, et al (1999). An advanced culture method for generating large quantities of highly pure Dendritic cells from mouse Bone Marrow. J Immunol Methods, 223, 77-92.
8. Meixlsperger S, Leung CS, Ramer PC, et al (2013). CD141+ dendritic cells produce prominent amounts of IFN-a after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood, 121, 5034-44.
9. Mellman I, Steinman RM (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell, 106, 255-8.
10. Nakagawa S, Wantanabe S, Yoshikawa H, et al (1995). Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of P53 in vitro. Virology, 212, 535-42.
11. Ohlschlager P, Quetting M, Alvarez G, et al (2009). Enhancement of immunogenicity of a therapeutic cervical cancer DNAbased vaccine by co-application of sequenceoptimized genetic adjuvants. Int J Cancer, 125, 189-98.
12. Palucka K, and Banchereau J (2012). Cancer immunotherapy via dendritic cells. Nat Rev Cancer, 12, 265-77.
13. Ramanathan P, Ganeshrajah S, Raghanvan R (2014). Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study. Asian Pac J Cancer Prev, 15, 5909-16.
14. Schlitzer A, McGovern N, Teo P, et al (2013). IRF4 Transcription factor-dependent CD11b (+) Dendritic cells in Human and mouse control Mucosal IL-17 Cytokine responses. Immunity, 38, 970-83.
15. Seo SH, Jin HT, Park SH, et al (2009). Optimal induction of Hpv DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine, 27, 5906-12.
16. Tanchot C, Terme M, Pere H, Tran, T, et al (2013). Tumorinfiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron, 6, 147-57.
17. Tran N, Hung C, Roden R, Wu T (2014). Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res, 193, 149-71.
18. Wu X, Liu X, Jiao Q (2014). Cytotoxic T Lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells. Asian Pac J Cancer Prev, 15, 2447-51.
19. Xie Q, Zhou Z, Li Z, Zeng Y (2011). Transforming activity of a novel mutant of HPV16 E6E7 fusion gene. Virol Sin, 26, 206-13
20. Yan J, Reichenbach DK, Corbitt N, et al (2009). Induction of antitumor immunity in vivo following delivery of a novel Hpv-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine, 27, 431-40.
21. Zhou Z, Zhao C, Li Q, Zeng Y (2014). A novel mutant of Human Papillomavirus Type 18 E6E7 fusion gene and its transforming activity. Asian Pac J Cancer Prev, 15, 7395-9.